Setomimycin
(Synonyms: 昔土米霉素) 目录号 : GC44884
A pre-anthraquinone
Cas No.:69431-87-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Setomimycin is a pre-anthraquinone originally isolated from S. pseudovenezuelae. It is active against a variety of Gram-positive bacteria, including S. aureus, B. subtilis, B. cereus, and M. smegmatis (MICs = 1.56-3.13 µg/ml). It also reduces tumor growth in a Sarcoma-180 mouse solid tumor model when administered at a dose of 200 mg/kg per day for seven days.
| Cas No. | 69431-87-4 | SDF | |
| 别名 | 昔土米霉素 | ||
| Canonical SMILES | CC(C(C(C)=O)C1=C(C2=C3C(C(CC(C)(O)C3C(C)=O)=O)=C(O)C4=C(O)C=CC=C24)C5=CC=CC(O)=C5C(O)=C16)=CC6=O | ||
| 分子式 | C34H28O9 | 分子量 | 580.6 |
| 溶解度 | Chloroform: soluble,DMSO: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7224 mL | 8.6118 mL | 17.2236 mL |
| 5 mM | 0.3445 mL | 1.7224 mL | 3.4447 mL |
| 10 mM | 0.1722 mL | 0.8612 mL | 1.7224 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Setomimycin as a potential molecule for COVID‑19 target: in silico approach and in vitro validation
Mol Divers 2023 Apr;27(2):619-633.PMID:35622309DOI:10.1007/s11030-022-10441-5.
COVID-19 pandemic caused by the SARS-CoV-2 virus has led to a worldwide crisis. In view of emerging variants time to time, there is a pressing need of effective COVID-19 therapeutics. Setomimycin, a rare tetrahydroanthracene antibiotic, remained unexplored for its therapeutic uses. Herein, we report our investigations on the potential of Setomimycin as COVID-19 therapeutic. Pure Setomimycin was isolated from Streptomyces sp. strain RA-WS2 from NW Himalayan region followed by establishing in silico as well as in vitro anti-SARS-CoV-2 property of the compound against SARS-CoV-2 main protease (Mpro). It was found that the compound targets Mpro enzyme with an IC50 value of 12.02 ± 0.046 μM. The molecular docking study revealed that the compound targets Glu166 residue of Mpro enzyme, hence preventing dimerization of SARS-CoV-2 Mpro monomer. Additionally, the compound also exhibited anti-inflammatory and anti-oxidant property, suggesting that Setomimycin may be a viable option for application against COVID-19 infections.
A new antibiotic, Setomimycin, produced by a strain of Streptomyces
J Antibiot (Tokyo) 1978 Nov;31(11):1091-8.PMID:721705DOI:10.7164/antibiotics.31.1091.
A new antibiotic, Setomimycin, was isolated from the culture broth of strain AM-2947, which was identified as Streptomyces pseudovenezuelae. The compound is a weakly acidic substance, and has UV-absorption at 228, 268 and 422 nm and a molecular formula of C34H28O9 (MW 580). It is active against Gram-positive bacteria including Mycobacteria, and has antitumor activity against Sarcoma-180 solid tumor in mice.
A biostatistical approach for augmenting rare bianthraquinone antibiotic production by Streptomyces sp. RA-WS2 using Taguchi design
AMB Express 2022 Dec 14;12(1):155.PMID:36515787DOI:10.1186/s13568-022-01497-5.
Consistent production of bioactives from microbial sources remains a big challenge for fermentation based bio-processes. Setomimycin, a rare 9,9'-bianthrylanthracene antibiotic reported to be active against Gram positive bacteria i.e. Staphyloccocus aureus, Bacillus subtilis, Bacillus cereus, and Mycobacterium smegmatis, including mycobacteria is one of the least exploited antibiotic. Present work aims to enhance and maximize Setomimycin production using One Factor at a Time (OFAT) approach, followed by Taguchi L9 orthogonal array (OA) design in 30L fermenter. Four most influential parameters, namely carbon source, nitrogen source, air and agitation were selected for optimization studies. The optimized production medium supplemented with 150 g/L glycerol and 7.5 g/L soyabean meal with an agitation rate of 100 RPM and air flow rate of 20 LPM (Liters Per Minute) resulted in 675 mg/L Setomimycin production within 96-108 h of fermentation as compared to the initial production i.e. 40 mg/L. Thus, an overall enhancement of 16.8 folds was achieved in Setomimycin production after optimization in 30L fermenter.
Identification and taxonomy of Streptomyces justiciae strain RA-WS2: a novel Setomimycin producing actinobacterium
3 Biotech 2023 Feb;13(2):47.PMID:PMC9837335DOI:10.1007/s13205-023-03459-5.
The taxonomic position of novel bianthraquinone antibiotic producer Streptomyces strain RA-WS2, a soil isolate from Shivalik region of NW Himalayas, India, has been described. The isolate produces Setomimycin as a major secondary metabolite under defined submerged fermentation conditions. 16S rRNA partial gene sequencing of the isolate indicated its closest similarity (99.4%) with Streptomyces cyaneochromogenes, followed by Streptomyces aquilus. However, the morphological characteristics i.e. colony colour, mycelium and spore chain arrangement were found to be close to Streptomyces aquilus. Therefore, a polyphasic approach was used for taxonomic positioning of the isolate. The Whole genome based similarity with 88.4% dDDH value, 98.65% ANI and 96.99% AAI value indicated its closest identity with Streptomyces justiciae. The taxonomic characteristics such as white colony with smooth surface, cylindrical spores arranged in straight chain, diffusible melanin production, high salt tolerance, 16S rRNA gene sequencing and phylogenomic studies, led to the identification of the strain as Streptomyces justiciae RA-WS2. The predicted biosynthetic gene clusters further confirmed the presence of the BGC for Setomimycin biosynthesis in Streptomyces justiciae strain RA-WS2. Supplementary information: The online version contains supplementary material available at 10.1007/s13205-023-03459-5.
Lincolnenins A-D: Isomeric Bactericidal Bianthracenes from Streptomyces lincolnensis
J Org Chem 2021 Aug 20;86(16):11011-11018.PMID:33320674DOI:10.1021/acs.joc.0c02492.
Cultivation profiling followed by chemical analysis of Streptomyces lincolnensis yielded four new isomeric bianthracenes, lincolnenins A-D (1-4), with relative stereostructures assigned on the basis of detailed spectroscopic analysis. Lincolnenins A (1) and B (2) exhibit restricted rotation about alternate bianthracene 9-9' and 9-8' bridges, respectively, and exist as single atropisomers, whereas C (3) and D (4) are thermally interconvertible atropisomers sharing a common 8-8' bianthracene bridge. Absolute configurations were assigned to 1-4 on the basis of diagnostic ROESY correlations and ECD calculations, whereas acid-mediated dehydration of 1 led to formation and revision of the absolute configuration of the biosynthetically related known Streptomyces antibiotic, Setomimycin (5). Lincolnenin A (1) exhibited significant bactericidal activity against multiple susceptible and drug-resistant Gram-positive pathogens (MIC99 < 2.0 μM), including Mycobacterium tuberculosis H37Ra (MIC99 = 0.9 μM).